Literature DB >> 31138891

Variants in regulatory elements of PDE4D associate with major mental illness in the Finnish population.

Vishal Sinha1,2,3, Liisa Ukkola-Vuoti1,2,3, Alfredo Ortega-Alonso1,2, Minna Torniainen-Holm1,2, Sebastian Therman1, Annamari Tuulio-Henriksson4, Pekka Jylhä1,5, Jaakko Kaprio2,6, Iiris Hovatta3,7, Erkki Isometsä5, Tyrone D Cannon8, Jouko Lönnqvist1,5, Tiina Paunio5,9, Jaana Suvisaari1, William Hennah10,11,12.   

Abstract

We have previously reported a replicable association between variants at the PDE4D gene and familial schizophrenia in a Finnish cohort. In order to identify the potential functional mutations underlying these previous findings, we sequenced 1.5 Mb of the PDE4D genomic locus in 20 families (consisting of 96 individuals and 79 independent chromosomes), followed by two stages of genotyping across 6668 individuals from multiple Finnish cohorts for major mental illnesses. We identified 4570 SNPs across the PDE4D gene, with 380 associated to schizophrenia (p ≤ 0.05). Importantly, two of these variants, rs35278 and rs165940, are located at transcription factor-binding sites, and displayed replicable association in the two-stage enlargement of the familial schizophrenia cohort (combined statistics for rs35278 p = 0.0012; OR = 1.18, 95% CI: 1.06-1.32; and rs165940 p = 0.0016; OR = 1.27, 95% CI: 1.13-1.41). Further analysis using additional cohorts and endophenotypes revealed that rs165940 principally associates within the psychosis (p = 0.025, OR = 1.18, 95% CI: 1.07-1.30) and cognitive domains of major mental illnesses (g-score p = 0.044, β = -0.033). Specifically, the cognitive domains represented verbal learning and memory (p = 0.0091, β = -0.044) and verbal working memory (p = 0.0062, β = -0.036). Moreover, expression data from the GTEx database demonstrated that rs165940 significantly correlates with the mRNA expression levels of PDE4D in the cerebellum (p-value = 0.04; m-value = 0.9), demonstrating a potential functional consequence for this variant. Thus, rs165940 represents the most likely functional variant for major mental illness at the PDE4D locus in the Finnish population, increasing risk broadly to psychotic disorders.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31138891     DOI: 10.1038/s41380-019-0429-x

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  40 in total

Review 1.  Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents.

Authors:  Claire Lugnier
Journal:  Pharmacol Ther       Date:  2005-08-15       Impact factor: 12.310

2.  A whole genome association study of neuroticism using DNA pooling.

Authors:  S Shifman; A Bhomra; S Smiley; N R Wray; M R James; N G Martin; J M Hettema; S S An; M C Neale; E J C G van den Oord; K S Kendler; X Chen; D I Boomsma; C M Middeldorp; J J Hottenga; P E Slagboom; J Flint
Journal:  Mol Psychiatry       Date:  2007-07-31       Impact factor: 15.992

3.  Different mutations in PDE4D associated with developmental disorders with mirror phenotypes.

Authors:  Anna Lindstrand; Giedre Grigelioniene; Daniel Nilsson; Maria Pettersson; Wolfgang Hofmeister; Britt-Marie Anderlid; Sarina G Kant; Claudia A L Ruivenkamp; Peter Gustavsson; Helena Valta; Stefan Geiberger; Alexandra Topa; Kristina Lagerstedt-Robinson; Fulya Taylan; Josephine Wincent; Tobias Laurell; Minna Pekkinen; Magnus Nordenskjöld; Outi Mäkitie; Ann Nordgren
Journal:  J Med Genet       Date:  2013-11-07       Impact factor: 6.318

4.  Exome sequencing identifies PDE4D mutations in acrodysostosis.

Authors:  Hane Lee; John M Graham; David L Rimoin; Ralph S Lachman; Pavel Krejci; Stuart W Tompson; Stanley F Nelson; Deborah Krakow; Daniel H Cohn
Journal:  Am J Hum Genet       Date:  2012-03-29       Impact factor: 11.025

5.  Genome-wide association study of patient-rated and clinician-rated global impression of severity during antipsychotic treatment.

Authors:  Shaunna L Clark; Renan P Souza; Daniel E Adkins; Karolina Aberg; József Bukszár; Joseph L McClay; Patrick F Sullivan; Edwin J C G van den Oord
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

6.  The cyclic AMP system and Drosophila learning.

Authors:  R L Davis; J Cherry; B Dauwalder; P L Han; E Skoulakis
Journal:  Mol Cell Biochem       Date:  1995 Aug-Sep       Impact factor: 3.396

7.  PDE4B polymorphisms and decreased PDE4B expression are associated with schizophrenia.

Authors:  S Hossein Fatemi; David P King; Teri J Reutiman; Timothy D Folsom; Jessica A Laurence; Susanne Lee; Yu-Ti Fan; Sara A Paciga; Marco Conti; Frank S Menniti
Journal:  Schizophr Res       Date:  2008-04-03       Impact factor: 4.939

8.  Positive association of the PDE4B (phosphodiesterase 4B) gene with schizophrenia in the Japanese population.

Authors:  Shusuke Numata; Shu-Ichi Ueno; Jun-Ichi Iga; Hongwei Song; Masahito Nakataki; Shin'ya Tayoshi; Satsuki Sumitani; Masahito Tomotake; Mitsuo Itakura; Akira Sano; Tetsuro Ohmori
Journal:  J Psychiatr Res       Date:  2008-03-10       Impact factor: 4.791

Review 9.  Physiology and biochemistry of Drosophila learning mutants.

Authors:  R L Davis
Journal:  Physiol Rev       Date:  1996-04       Impact factor: 37.312

10.  The PDE4B gene confers sex-specific protection against schizophrenia.

Authors:  Benjamin S Pickard; Philippa A Thomson; Andrea Christoforou; Kathryn L Evans; Stewart W Morris; David J Porteous; Douglas H R Blackwood; Walter J Muir
Journal:  Psychiatr Genet       Date:  2007-06       Impact factor: 2.458

View more
  4 in total

1.  Single-nucleus RNA sequencing of midbrain blood-brain barrier cells in schizophrenia reveals subtle transcriptional changes with overall preservation of cellular proportions and phenotypes.

Authors:  Sofía Puvogel; Astrid Alsema; Laura Kracht; Cynthia Shannon Weickert; Iris E C Sommer; Bart J L Eggen; Maree J Webster
Journal:  Mol Psychiatry       Date:  2022-10-03       Impact factor: 13.437

2.  Protection from Amyloid β Peptide-Induced Memory, Biochemical, and Morphological Deficits by a Phosphodiesterase-4D Allosteric Inhibitor.

Authors:  Su-Ying Cui; Ming-Xin Yang; Yong-He Zhang; Victor Zheng; Han-Ting Zhang; Mark E Gurney; Ying Xu; James M O'Donnell
Journal:  J Pharmacol Exp Ther       Date:  2019-09-05       Impact factor: 4.030

3.  Mapping Phosphodiesterase 4D (PDE4D) in Macaque Dorsolateral Prefrontal Cortex: Postsynaptic Compartmentalization in Layer III Pyramidal Cell Circuits.

Authors:  Dibyadeep Datta; John F Enwright; Dominique Arion; Constantinos D Paspalas; Yury M Morozov; David A Lewis; Amy F T Arnsten
Journal:  Front Neuroanat       Date:  2020-11-20       Impact factor: 3.856

4.  Recursive splicing is a rare event in the mouse brain.

Authors:  Sohyun Moon; Ying-Tao Zhao
Journal:  PLoS One       Date:  2022-01-28       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.